[go: up one dir, main page]

MX2023009584A - Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos. - Google Patents

Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.

Info

Publication number
MX2023009584A
MX2023009584A MX2023009584A MX2023009584A MX2023009584A MX 2023009584 A MX2023009584 A MX 2023009584A MX 2023009584 A MX2023009584 A MX 2023009584A MX 2023009584 A MX2023009584 A MX 2023009584A MX 2023009584 A MX2023009584 A MX 2023009584A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
methods
making
bed bug
bug monoclonal
Prior art date
Application number
MX2023009584A
Other languages
English (en)
Inventor
Min Wang
William John Hall
Original Assignee
Redcoat Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redcoat Solutions Inc filed Critical Redcoat Solutions Inc
Publication of MX2023009584A publication Critical patent/MX2023009584A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B22F1/0545—Dispersions or suspensions of nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0043—Preparation of sols containing elemental metal
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2301/00—Metallic composition of the powder or its coating
    • B22F2301/25—Noble metals, i.e. Ag Au, Ir, Os, Pd, Pt, Rh, Ru
    • B22F2301/255—Silver or gold
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/054—Particle size between 1 and 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/056—Particle size above 100 nm up to 300 nm
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción proporciona anticuerpos monoclonales anti-chinches y fragmentos de los mismos que unen antígeno, así como composiciones y kits que comprenden los mismos. La presente descripción también proporciona métodos de elaboración de anticuerpos monoclonales y fragmentos de los mismos que unen antígeno, y métodos de uso de los mismos para detectar chinches.
MX2023009584A 2015-10-21 2018-04-23 Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos. MX2023009584A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562244189P 2015-10-21 2015-10-21

Publications (1)

Publication Number Publication Date
MX2023009584A true MX2023009584A (es) 2023-08-23

Family

ID=58558142

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004986A MX2018004986A (es) 2015-10-21 2016-10-21 Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
MX2023009584A MX2023009584A (es) 2015-10-21 2018-04-23 Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018004986A MX2018004986A (es) 2015-10-21 2016-10-21 Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.

Country Status (14)

Country Link
US (3) US10768172B2 (es)
EP (2) EP3365367B1 (es)
AU (2) AU2016342373B2 (es)
CA (1) CA3041460A1 (es)
ES (1) ES2953484T3 (es)
HR (1) HRP20231035T1 (es)
HU (1) HUE063822T2 (es)
MA (1) MA45831B1 (es)
MD (1) MD3365367T2 (es)
MX (2) MX2018004986A (es)
PL (1) PL3365367T3 (es)
RS (1) RS64530B1 (es)
SM (1) SMT202300278T1 (es)
WO (1) WO2017070603A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202500064T1 (it) 2015-10-21 2025-03-12 Redcoat Solutions Inc Dispositivo per il rilevamento delle cimici dei letti
US10768172B2 (en) * 2015-10-21 2020-09-08 Redcoat Solutions, Inc. Anti-bed bug monoclonal antibodies and methods of making and uses thereof
EP4056033B1 (en) 2017-05-22 2023-09-06 Corteva Agriscience LLC Selective detection of bed bugs
SG11202105191VA (en) 2018-11-21 2021-06-29 Dow Agrosciences Llc Selective detection of bed bugs

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
AU4562599A (en) 1998-06-12 1999-12-30 New Horizons Diagnostics, Inc. Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles
DE50001665D1 (de) 1999-10-12 2003-05-08 Connex Ges Zur Optimierung Von Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7214542B2 (en) 2003-01-30 2007-05-08 Michael Hutchinson Method of processing assay test results
US7220597B2 (en) 2003-01-30 2007-05-22 Zin Benedict L Assay test device and method of making same
WO2004084841A2 (en) * 2003-03-27 2004-10-07 Heska Corporation Novel anti-feline albumin antibodies and methods of detecting early renal disease
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
WO2007014344A2 (en) 2005-07-27 2007-02-01 Cytosignet, Inc. Detection and measurement of blood-feeding activity
US7591099B2 (en) 2005-08-30 2009-09-22 Ecolab Inc. Bed bug monitor
AU2013200548B2 (en) 2006-10-23 2015-06-18 Ecolab Usa Inc. Bedbug detection, monitoring and control techniques
US7743552B2 (en) 2006-10-23 2010-06-29 Dow Agrosciences Llc Bedbug detection, monitoring and control techniques
WO2008073895A2 (en) 2006-12-08 2008-06-19 Binax, Inc. Methods and devices for testing saliva
EP1933145B1 (en) 2006-12-11 2011-09-28 AraGen Biotechnology Co. Ltd. Rapid immunochromatographic detection by amplification of the colloidal gold signal
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2680613A1 (en) 2007-03-13 2008-09-18 National Jewish Medical And Research Center Methods for generation of antibodies
JP2010525322A (ja) 2007-04-20 2010-07-22 クイデル コーポレイション 統合乾燥剤付きの分析装置
US20090155921A1 (en) 2007-12-12 2009-06-18 Arbor Vita Corporation Method and apparatus for reading test strips
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
GB0809995D0 (en) 2008-05-31 2008-07-09 Spd Swiss Prec Diagnostics Gmb Assay device
GB0900669D0 (en) 2009-01-16 2009-02-25 Bed Bugs Ltd Pest control
US20100212213A1 (en) 2009-02-25 2010-08-26 Hope Iii Joe Harold Detection device and method for monitoring bed bug infestation
JP2012520315A (ja) 2009-03-13 2012-09-06 エフ エム シー コーポレーション トコジラミを誘引するための組成物
US8577986B2 (en) 2010-04-02 2013-11-05 Microsoft Corporation Mapping RDMA semantics to high speed storage
US20110289824A1 (en) 2010-05-28 2011-12-01 Tai-Teh Wu Compounds, methods, and devices for detecting and/or treating insect infestation
FI20115285A0 (fi) 2011-03-24 2011-03-24 Reagena Ltd Oy Menetelmä pikatestin suorittamiseksi
US9458512B2 (en) 2011-07-05 2016-10-04 Ernest Colaizzi Kit for the detection of bed bugs
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
WO2013096817A2 (en) 2011-12-23 2013-06-27 Abbott Point Of Care Inc Integrated test device for optical detection of microarrays
WO2013130613A1 (en) 2012-02-29 2013-09-06 Sri International Ectoparasite detection
US20130208114A1 (en) 2013-01-25 2013-08-15 Jody Arthur Balsam Digital Bedbug Indicator: A bedbug insect peripheral electronic detection unit device
GB2524307B (en) 2014-03-20 2016-04-20 Rentokil Initial Plc Apparatus
CN106461646A (zh) 2014-04-17 2017-02-22 Z集成数字技术有限公司 电子测试装置数据通信
AU2016315370A1 (en) 2015-08-31 2018-04-26 Airmid Health Group Limited Novel proteins and detection methods
US10768172B2 (en) * 2015-10-21 2020-09-08 Redcoat Solutions, Inc. Anti-bed bug monoclonal antibodies and methods of making and uses thereof
SMT202500064T1 (it) * 2015-10-21 2025-03-12 Redcoat Solutions Inc Dispositivo per il rilevamento delle cimici dei letti

Also Published As

Publication number Publication date
AU2016342373A1 (en) 2018-06-07
RS64530B1 (sr) 2023-09-29
US20170137501A1 (en) 2017-05-18
US20250026817A1 (en) 2025-01-23
EP3365367A1 (en) 2018-08-29
CA3041460A1 (en) 2017-04-27
MX2018004986A (es) 2019-01-14
US20200363405A1 (en) 2020-11-19
US10768172B2 (en) 2020-09-08
EP4273235A2 (en) 2023-11-08
WO2017070603A1 (en) 2017-04-27
MA45831B1 (fr) 2023-10-31
SMT202300278T1 (it) 2023-09-06
HRP20231035T1 (hr) 2023-12-22
WO2017070603A9 (en) 2018-05-17
ES2953484T3 (es) 2023-11-13
HUE063822T2 (hu) 2024-02-28
EP3365367A4 (en) 2019-06-12
EP3365367B1 (en) 2023-06-07
EP4273235B1 (en) 2025-04-09
MD3365367T2 (ro) 2024-02-29
EP3365367C0 (en) 2023-06-07
EP4273235C0 (en) 2025-04-09
EP4273235A3 (en) 2024-01-17
US12030933B2 (en) 2024-07-09
MA45831A (fr) 2019-06-12
PL3365367T3 (pl) 2023-10-30
AU2016342373B2 (en) 2023-09-21
AU2023282327A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12016501366A1 (en) Novel anti-baff antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
MX2022002364A (es) Anticuerpos anti-pd-l1.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
MX388181B (es) Anticuerpos anti-pd-1.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
PH12020550908A1 (en) Anti-cxcr5 antibodies and compositions and uses thereof
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PH12019502694A1 (en) Anti-trkb antibodies
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2018001465A (es) Nuevos anticuerpos anti-gpvi humana y sus usos.
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.